A within-host mathematical model to describe the dynamics of target cells and viral load in early HIV-1 infection was developed, which incorporates a combination of RTI and PI treatments by using a pharmacokinetics model. The local stability of uninfected steady state for the model was determined using an alternative threshold. The pharmacokinetics model was employed to estimate drug efficacy in multiple drug dosing. The effect of periodic drug efficacy of pharmacokinetic type on outcome of HIV-1 infection was explored under various treatment interruptions. The effectiveness of treatment interruption was determined according to the time period of the drug holidays. The results showed that long drug holidays lead to therapy failure. Under interruption of treatments combining RTI and PI therapy, effectiveness of the treatment requires a short duration of the drug holiday.
Introduction
The human immunodeficiency virus type 1 (HIV-1) is a retrovirus that infects the cells of the immune system expressing receptor CD4 and co-receptor CCR5 on their surfaces [1] . When HIV enters into the individual's body via epithelium mucosa, it attacks target cells such as Langerhans cells and CD4 + T cells in the genital mucosal. The spread of the HIV infection in the genital tract can occur through cell-to-cell contact or virus-to-cell contact [2] .
Highly active anti-retroviral therapy (HAART) is one of the HIV treatment strategies that is effective through suppressing the viral load. It has a combination of one or more reverse transcriptase inhibitors (RTIs) as well as protease inhibitors (PIs). RTI drugs prevent infection of target cells, while PI drugs prevent active infected target cells from producing infectious virus particles [3] .
A number of in-host HIV-1 infection dynamic models have been developed to study the effects of antiretroviral (ARV) therapy and theoretically associating it to the development of treatment strategies for HIV-infected individuals [4] [5] [6] [7] [8] [9] [10] . A simple dynamic model of RTI monotherapy was proposed by Srivastava, et al. [6] , classifying the infected CD4 + T cells into two categories, namely the class of infected CD4 + T cells in the process of acquiring a pre-RTI drug and the class of infected CD4 + T cells having fully acquired the RTI drug. Their results suggested that the HIV infection is cleared when the drug efficacy exceeds a critical value. De Leenheer [7] employed a standard model incorporating treatment by using a piecewise constant periodical signal to approximate drug efficiency. The results of the study showed that HIV infection is cleared more quickly when the drug is more efficient and effective over a longer time period.
A similar model incorporating RTI and PI therapies is proposed in [8] in order to assess the impact of therapy on the dynamics of the disease due to imperfect adherence and emergence of drug resistance to the treatment regime. The efficacy functions were modeled by bang-bang and single-dose pharmacokinetic type. The average drug efficacy formulated from the single-dose pharmacokinetics model was used to investigate the outcome of HIV infection during ARV treatment under different scenarios. The results of the study suggested that PIs are more efficient than RTIs when used as monotherapy and that a combination of RTIs and PIs is more effective than monotherapy. Using a simple model of ARV therapy with constant efficacy, Perelson [10] revealed the dynamics of the HIV viral load and provided insight in the development of drug therapies. The study focused only on CD4 + T cells as target cells for HIV.
Chirove, et al. [11] have proposed an in-host HIV-1 infection model that captures the interaction between the free virus, Langerhans cells and CD4 + T cells during early HIV infection. The results from their study showed that viral degradation slows down the progression of the HIV infection, whereas viral lysis increases the HIV infection. Sutimin, et al. [12] modified the model in [11] to incorporate a combination of RTI and PI drugs administered periodically. For periodical drug dosing, a pharmacokinetics profile of the drug concentration was used by considering steady state pharmacokinetics. The results from the study suggested that suboptimal adherence and drug resistance cause treatment failure.
More realistic models need to capture drug efficacy as a function of periodic pharmacokinetics with multi-dosing. This enables one to realistically capture drug accumulation in the plasma before administering the next dose. Pharmacokinetics of drugs in the body during drug administration varies over time due to the processes of drug absorption, distribution and metabolism in the body, which take place at variable rates [13] . Thus, the drug concentration in the body is also determined by the drug content in the body before administering the drug for the next drug dosing. The continuous uptake of HAART was met with a number of challenges. It was proved that there is rapid waning of adherence by the patients. This is associated with increased myocardial infarction rates, putting individuals at risk of coronary artery disease or accelerated liver disease due to metabolic effects of HAART. On the other hand, high medical costs impede efforts to increase the efficacy of HAART. One of the strategies to avert the aforementioned effects is the introduction of drug holidays. There are two types of drug holidays, namely time-dependent holidays and CD4 count-dependent holidays. CD4 count-defined holidays have been extensively used, whereas little attention has been given to time-dependent holidays, even though they have the potential to optimize ARV therapy [14] . The safety and efficacy of time-dependent drug holidays still remains to be determined.
Available evidence reflects that HIV transmission occurs on different immune cells. Focusing on CD4
+ T cells only may underestimate the actual impact of the HIV infection. Furthermore, various transmission mechanisms of infection such as cell-to-cell transmission also contribute to HIV invasion of the immune system [2, 9] .
In this paper, we use the model from [12] and emphasize the importance of using pharmacokinetics as a realistic way to capture the effects of RTIs and PIs. Unlike in [12] , our objective was to investigate the impact of multiple drug dosing, incorporating drug accumulation with drug holidays in combined RTI and PI therapies on HIV-1 infection. We considered that the drugs are only effective on wild-type virus and do not take into account drug-resistant mutant strains, mutants due to copying errors, or mutants due to the virus changing its genome. We have carried out analysis of the uninfected steady state and investigated numerically the consequences of different treatment scenarios and their impact on the evolution of both the host cells and the free virus. 
.
The parameters of RTI Eqs. (1) and (2) describe susceptible Langerhans and CD4 + T cells. We assume that they are produced in the body at constant rates λ l and π, respectively. HIV infection of Langerhans cells is inhibited by the degradation mechanism in the respectively. Eqs. (3) and (4) In Eq. (5), the population of infected Langerhans cells is produced from both susceptible Langerhans cells and Langerhans cells in the process of acquiring active drugs that become newly infected cells. It diminishes due to the natural and viral lysis death at constant rates μ l, ρ, respectively. In Eq. (6), the population of infected CD4 + T cells is generated from both susceptible CD4 + T cells and CD4 + T cells with active drugs that become newly infected cells, and diminishes due to natural and viral lysis death at constant rates μ, α, respectively. Eq. (7) describes the free virus population. The death of target cells due to viral lysis induces the free virus production of infected target cells that supplies the free virus population. Once the target cells acquire active drugs, the average of the infectious virus production by actively infected CD4 + T cells and infected Langerhans cells is reduced to (1 ) 
respectively, due to PI drug action in blocking infectious virion production. The free virus population decreases due to degradation of healthy Langerhans cells and Langerhans cells with active drugs at constant rate ϕ, and it dies at constant rate μ v .
Model Analysis
We recall that the basic reproductive number, 0 ,  is the average number of secondary infections of target cells that are generated when one infected cell or virus is introduced into a susceptible cell population. The next generation matrix [18] of the model Eq. (1) -Eq. (7) is given by 
where,  that provides a significant biological interpretation. The characteristic polynomial of matrix G is
, where
Following the analysis in [11] , the parameter 
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We note that the quantities [11] , the additional drug active classes make the computation of the endemic equilibrium point complicated and difficult to express in closed form. We used the instability conditions of the disease-free equilibrium to infer the existence of the endemic equilibrium point.
Stability of the Uninfected Steady State
When the virus is not detected in the plasma or fully suppressed in the body during ARV treatment, the system possesses an uninfected steady state. The uninfected steady state of the model is given by 
The eigenvalues of
, the others satisfy the equation 3 2
We see that 2 In the next section, we study the drug pharmacokinetics in the body when the drug is administered periodically and orally, and also formulate the drug concentration as a periodic function of the pharmacokinetics model.
Time-varying Drug Efficacy of Multiple Dose Pharmacokinetics
Pharmacokinetics is the concept that explains the kinetics of absorption, distribution and elimination of drugs inside the body. We describe the plasma concentration of the drug assuming that the body is a one-compartment model. In dosing the drug orally, the drug concentration in the body rises rapidly, which is characterized by absorption and distribution in the body. After achieving its maximum, it decreases slowly due to elimination from the body [3, 19] . We define the drug concentration in an initial single dose as follows,
where  is the drug dosing interval, 1/2 t is the serum half-life,
, and max T is the time when the drug achieves peak concentration. In multiple dosing, the drug concentration in the body at the next dose is higher due to drug accumulation from previous doses. We use the concentration function in Eq. (11) to formulate the drug concentration in the body in multiple dosing. By using the superposition principle, the actual drug concentration in the body in the th ( 1) n  dosing cycle,
We define the drug efficacy function [19] as
, where   C t is the drug concentration and IC 50 is the drug concentration required for inhibiting viral replication by 50%.
The concentration and efficacy evolutions for each RTI and PI drug in the body in multiple drug dosing are presented in the next section.
Simulation Results
We performed numerical simulations to describe the implications of RTI and PI treatments modeled by pharmacokinetic type with respect to the dynamics of free virus load, Langerhans and CD4 + T cells for early HIV-1 infection. In this section, we explore the outcomes of the effects of structured treatment interruption (drug holidays) in varying strategies. Firstly, we present the evolution of the concentration and efficacy of both RTI and PI drugs under perfect adherence in accordance with the recommendations. Secondly, we illustrate the time course of the concentration and effectiveness of both RTI and PI during continuous drug administration followed by a 1-day drug holiday. Thirdly, we investigate numerically the outcomes of combined RTI and PI drug-holiday treatments for various scenarios in drug administering during 160 days. The values of the pharmacokinetic parameters are given in Table 1 . The parameter values of the model were taken from [11] and are given in Table 2 . Figure 1 shows that in RTI class, the concentration of delavirdine reached the steady state condition after a longer time compared to the other drugs. In the PI class, the amprenavir concentration achieved the steady state condition after a longer time period compared to the other drugs. We see that efavirenz had higher effectiveness compared to delavirdine, despite the fact that the concentration of efavirenz was lower. In Figure 2 , we observe the outcomes of treatment interruption of both RTI and PI associated with their concentration and effectiveness. In this case, we consider the cycles of treatment involving 5 days continuous treatment followed by a 1-day drug holiday. Figure 2 shows that, in the RTI class, the effectiveness of efavirenz decreased more quickly compared to the other drugs, whilst in the PI class, the effectiveness of indinavir decreased more sharply compared to the other drugs. Next, we studied the outcome of ARV therapy under different drug-holiday strategies in drug administration during 160 days. The average drug holiday of the different treatment strategies was about 24 days. The treatment scenarios can be described as follows. Firstly, therapy involving cycles of treatment with CD4 T  a combination of delavirdine and ritonavir administered continuously for 5 days followed by a 1-day interruption. Secondly, therapy involving cycles of treatment with a combination of delavirdine and ritonavir administered continuously for 10 days followed by a 2-day interruption. Lastly, treatment with a combination of delavirdine and ritonavir administered continuously for 20 days followed by a 4-day interruption and the cycle of the treatment being repeated continuously. Figure 3 shows that in the treatment cycles involving a 1-day interruption, the number of healthy target cells still increased. The treatment cycles involving a 4-day interruption led to the number of healthy target cells decreasing rapidly with oscillations (see Figure 3 (a) and Figure 3(b) ). The decrease is associated with the increase of the number of infected target cells and of the free virus in an oscillatory manner (see Figure 3 (c) and Figure 3(d) ).
Conclusion
In this paper, the impact of multiple drug dosing incorporating drug accumulation with drug holidays in combined RTI and PI therapies on HIV-1 infection was investigated. A model incorporating some of the target cells for HIV encountered during early HIV infection, i.e. Langerhans cells and CD4 + T cells was constructed. Mathematical analysis of the infection-free equilibrium point was done using an alternative threshold that provided conditions under which the infection may progress, i.e. when the infection-free equilibrium is unstable. This instability condition was used to come up with a representative scenario of infection progression and under this scenario we numerically investigated the outcomes of drug-holiday treatments in early HIV-1 infection considering that the drugs are administered orally and periodically. A pharmacokinetics model was used to calculate the drug efficacy of RTI and PI drugs as a periodic time-varying function. The evolution of the drug concentrations for multiple drug dosing was modeled more realistically by considering the drug accumulation in the body before the next dose was administered.
Also, the drug pharmacokinetics were modeled to formulate the drug concentration in the body and the effects of various treatment regiments on the outcome of early HIV-1 infection corresponding to the number of Langerhans cells, CD4  T cells, and viral load. It is important to know the time duration of the drug holidays during ARV therapy. Our results provide insight for administration of drugs using drug-holiday strategies during early HIV infection. Our results suggest that periodic drug holidays are more effective if the time duration of the drug holidays is shorter, when the drugs are administered continuously for 5 days followed by a 1-day interruption. Our results are supported by other studies, such as [20] , although the authors recommend 5-day on and 2-day treatment interruptions. Benson [21] suggests that safe treatments may require short interruptions, although he does not specify precisely what duration of interruption. The concept of periodic drug efficacy according to pharmacokinetic type provides insight into ARV therapies in prognosis of HIV-1 infection. This study can be further developed to explore the optimum control problems, including structured treatment interruptions, as an important strategy for antiretroviral therapy to suppress virus replication.
